熱門資訊> 正文

Omeros在第二季度的节拍上激增

2026-08-13 21:36

奧麥羅製藥(OMER) 0
stem inc(STEM) 0

Omeros (OMER) is up ~29% in Thursday trading after posting Q2 financial results following Wednesday's closing bell that beat on both lines.
Results were helped by a 190% increase compared to Q1 in sales of Yartemlea (narsoplimab), its treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, to $32.2M.
Q2 non-GAAP GPS of $0.02 compares to a loss of $0.57 in the year-ago period.
In Q2, the company repurchased an additional 489,000 shares of common stock.
Omeros ended the quarter (June 30) with cash and short-term investments of ~$132M compared to ~$171.8M on Dec. 31, 2025.

More on Omeros

Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript
Omeros: Yartemlea Faces Headwinds While We Wait On Pipeline Developments
Omeros: Launch Traction Encouraging, But Risk/Reward Looks Balanced (Initiating Hold)
Omeros outlines Q3 2026 interest expense of about $6.5M while advancing $287,000 NTAP for YARTEMLEA
Omeros Q2 2026 Earnings Preview

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。